Table 1.
First author | Ref. | Year | Gy | Pt No. | Median PTV, cc | Median follow-up in months | G2- RP | G3 RP | G4 RP | G5 RP | RP factor 1 | RP factor 2 |
Onishi | [32] | 2004 | 18-75Gy/1-25Fr | 245 | NA | 24 | 6.50% | 1.20% | 1.20% | 0% | ||
McGarry | [31] | 2005 | 24Gy/3Fr | 47 | NA | NA | 8.40% | 4.30% | 2.10% | 0% | ||
Takahashi | [40] | 2006 | 15-30Gy | 32 | NA | 18 | 12.50% | 0% | 6% | |||
Yamashita | [8] | 2007 | 48Gy/4-6Fr | 25 | 43.9 | 17 | 28.00% | 4% | 4% | 12% | CI | |
Baumann | [16] | 2008 | 45Gy/3Fr | 60 | NA | 23 | NA | 21% | 0% | 0% | ||
Ricardi | [27] | 2009 | 45Gy/3Fr or 26Gy/1Fr | 60 | NA | 30.9 | 14.30% | 3.20% | 0% | 0% | MLD | |
Borst | [10] | 2009 | 35-60Gy/4-8Fr | 128 | 9.6 | 16.1 | 10.90% | 0.80% | 0% | 0% | MLD | |
Stephans | [13] | 2009 | 60Gy/3Fr or 50Gy/5Fr | 86 | 39.9/30.4 | 15.3 | 2.30% | 0% | 0% | 0% | ||
Rusthoven | [2] | 2009 | 48-60Gy/3Fr | 7 | NA | 15.4 | 2.60% | |||||
Yamashita | [39] | 2010 | 48Gy/4Fr | 117 | NA | 14.7 | NA | 1.70% | 1.70% | 6.00% | KL-6 and SP-D | IP-shadow |
Timmerman | [23] | 2010 | 60Gy/3Fr or 54Gy/3Fr | 55 | NA | 34.4 | NA | 12.70% | 3.60% | 0% | ||
Nagata | [20] | 2010 | 48Gy/4Fr | 104 | NA | 46.8 | NA | 6.20% | 0% | 0% | ||
Guckenberger | [9] | 2010 | 26Gy/1Fr or 37.5Gy/3Fr | 59 | 33 | 13 | 18.60% | 0% | 0% | 0% | MLD | V2.5-50 |
Ong | [28] | 2010 | 55Gy/5Fr or 60Gy/8Fr | 18 | 137 | 12.8 | 27.80% | 11.10% | 0% | 0% | V5 | |
Grills | [35] | 2010 | 48Gy/4Fr or 60Gy/5Fr | 58 | NA | 30 | 11% | 2% | 0% | 0% | ||
Stauder | [30] | 2011 | 32-60Gy/3-5Fr | 74 | 42.9 | 15.8 | 12.50% | 2.30% | 0% | 1.10% | Max dose | |
Matsuo | [53] | 2012 | 48Gy/4Fr | 74 | 32.5 | 31.4 | 20.30% | 1.40% | 0% | 0% | V25 | PTV volume |
Barriger | [29] | 2012 | 24-66Gy/3-5Fr | 84 | 48.3 | 17 | 9.40% | 2% | 0.40% | 0% | MLD (4Gy) | V20 (4%) |
Baker | [37] | 2013 | Multiple | 240 | 37.6 | 15.6 | 11% | 1.10% | 0% | 0% | MLD (6Gy) | V20 (10%) |
MLD: Mean lung dose; NA: Not available.